Drug intelligence / Profile preview

DNK-651

Development stage: Unknown
Lead developer: Denka
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous

Overview

DNK-651 is a virus-like particle (VLP) vaccine candidate developed by Denka (formerly Denka Seiken) for the prevention of norovirus infection. Noroviruses are a leading cause of acute gastroenteritis worldwide, and currently, no licensed vaccines are available. DNK-651 is designed to elicit a protective immune response against norovirus by mimicking the viral structure without containing genetic material. It is being evaluated in early-stage clinical trials in Japan, specifically investigating safety and immunogenicity via intradermal and subcutaneous administration routes in both young and elderly healthy adults.

Targets

Norovirus VP1STING (Stimulator of interferon genes protein)TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on DNK-651.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNK-651.

Explore the full profile